Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

To compare the effectiveness and safety of cefazolin versus cloxacillin for the treatment of infective endocarditis (IE) due to methicillin-sensitive Staphylococci (MSS). Data were retrospectively collected on patients treated for a definite MSS endocarditis who received cefazolin or cloxacillin for at least 10 consecutive days in six French hospitals between January-1 2014 and December-31 2020. The primary endpoint was treatment failure defined as a composite of death within 90 days of starting antibiotherapy, or embolic event during antibiotherapy, or relapse of IE within 90 days of stopping antibiotherapy. We used Cox regression adjusted for the inverse probability of treatment weighting of receiving cefazolin. 192 patients were included (median age 67.8 years). IE was caused by S.aureus in 175 (91.1%) and by coagulase-negative staphylococci in 17 (8.9%). Ninety-four patients (48.9%) received cefazolin, and 98 (51%) received cloxacillin. 34 patients (34.7%) with cefazolin and 26 (27.7%) with cloxacillin met the composite primary endpoint, with no significant differences between groups (adjusted HR = 1.13, 95% CI 0.63 to 2.03). There were no significant differences in secondary efficacy endpoints or biological safety events. The effectiveness of cefazolin did not significantly differ from cloxacillin for the treatment of MSS endocarditis. © 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Citation

Anne-Laure Destrem, Alexis Maillard, Mathieu Simonet, Soline Simeon, Adrien Contejean, Clémentin Vignau, Lucas Pires, Margaux Isnard, Virginie Vitrat, Tristan Delory, Mylène Maillet. Effectiveness and safety of cefazolin versus cloxacillin in endocarditis due to methicillin-susceptible Staphylococcus spp.: a multicenter propensity weighted cohort study. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2024 Aug;43(8):1569-1577

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 38806841

View Full Text